Cordova Ezequiel, Lespada M Ines, Cecchini Diego, Nieto Fabiola, Palonski Susana, Badran Mariana, Bernasconi Silvina, Bacelar Brenda, Morganti Laura, Garibaldi Franco, Bermejo Veronica, Aguirre Viviana, Badia Marcela, Rodriguez Claudia G
Unidad de Infectología, Hospital Cosme Argerich, Buenos Aires, Argentina.
Laboratorio Central, Hospital Cosme Argerich, Buenos Aires, Argentina.
Vacunas. 2022 May;23:S14-S21. doi: 10.1016/j.vacun.2022.01.008. Epub 2022 Feb 14.
Vaccination for COVID-19 in healthcare workers (HCW) is essential to protect one of the populations most exposed to this disease. However, data on the humoral response rate to the vaccine and the factors associated with it in this population are limited. Therefore, we aimed to evaluate the antibody response against SARS-CoV-2 in HCWs with complete Sputnik V vaccine scheme and factors associated with an increased antibody response.
Prospective study to evaluate the anti-SARS-CoV-2 humoral response in HCWs vaccinated with two doses of the Sputnik V vaccine (April-July 2021). The assessment of anti-Spike IgG antibodies in plasma was performed using the COVIDAR IgG enzyme-linked immunosorbent assay. A logistic regression was performed to identify independent factors associated with a positive IgG serology test and an elevated antibody response.
A total of 630 HCWs were enrolled. Median age (IQR): 47 years (35-56). Female sex: 462 (73.33%). Previous COVID-19: 158 (25%). The median interval time between vaccine doses was 3 (3-4) weeks. Positive serology was observed in 607 (96.35%) HCWs. In the multivariate analysis, a history of systemic reactogenicity was identified as an independent variable associated with a positive serology; and history of systemic reactogenicity, COVID-19, interval between doses ≥ 4 weeks and time to serology < 14 weeks were associated with an elevated antibody response.
This study provides data on the humoral response to the Sputnik V vaccine in a real-life setting. These initial data can contribute to the development of future immunization strategies in HCWs.
医护人员接种新冠病毒疫苗对于保护这一最易感染该疾病的人群至关重要。然而,关于该人群对疫苗的体液免疫反应率及其相关因素的数据有限。因此,我们旨在评估完成卫星五号疫苗接种方案的医护人员对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体反应以及与抗体反应增强相关的因素。
一项前瞻性研究,旨在评估2021年4月至7月接种两剂卫星五号疫苗的医护人员对SARS-CoV-2的体液免疫反应。使用COVIDAR IgG酶联免疫吸附测定法检测血浆中抗刺突蛋白IgG抗体。进行逻辑回归分析以确定与IgG血清学检测呈阳性和抗体反应增强相关的独立因素。
共纳入630名医护人员。年龄中位数(四分位间距):47岁(35 - 56岁)。女性:462名(73.33%)。既往感染过新冠病毒:158名(25%)。两剂疫苗接种的中位间隔时间为3(3 - 4)周。607名(96.35%)医护人员血清学检测呈阳性。在多变量分析中,全身反应原性病史被确定为与血清学检测呈阳性相关的独立变量;全身反应原性病史、既往感染新冠病毒、接种间隔时间≥4周以及血清学检测时间<14周与抗体反应增强相关。
本研究提供了现实环境中卫星五号疫苗体液免疫反应的数据。这些初步数据有助于制定未来医护人员的免疫策略。